Prime Medicine Inc (NASDAQ: PRME) kicked off on Friday, up 15.26% from the previous trading day, before settling in for the closing price of $3.80. Over the past 52 weeks, PRME has traded in a range of $3.28-$9.86.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -25.00% over the past five years. While this was happening, its average annual earnings per share was recorded 25.11%. With a float of $39.57 million, this company’s outstanding shares have now reached $97.38 million.
Let’s look at the performance matrix of the company that is accounted for 234 employees. In terms of profitability, gross margin is 94.66%, operating margin of -560.15%, and the pretax margin is -545.19%.
Prime Medicine Inc (PRME) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Prime Medicine Inc is 67.03%, while institutional ownership is 36.60%. The most recent insider transaction that took place on Feb 15 ’24, was worth 20,000,000. In this transaction Director of this company bought 3,200,000 shares at a rate of $6.25, taking the stock ownership to the 3,200,000 shares. Before that another transaction happened on Feb 15 ’24, when Company’s 10% Owner bought 3,200,000 for $6.25, making the entire transaction worth $20,000,000. This insider now owns 3,200,000 shares in total.
Prime Medicine Inc (PRME) Latest Financial update
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -0.55 earnings per share (EPS), lower than consensus estimate (set at -0.46) by -0.09. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.45 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 25.11% per share during the next fiscal year.
Prime Medicine Inc (NASDAQ: PRME) Trading Performance Indicators
Take a look at Prime Medicine Inc’s (PRME) current performance indicators. Last quarter, stock had a quick ratio of 8.23. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 891.07.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.13, a number that is poised to hit -0.38 in the next quarter and is forecasted to reach -1.40 in one year’s time.
Technical Analysis of Prime Medicine Inc (PRME)
Prime Medicine Inc (NASDAQ: PRME) saw its 5-day average volume 1.27 million, a positive change from its year-to-date volume of 0.98 million. As of the previous 9 days, the stock’s Stochastic %D was 83.27%. Additionally, its Average True Range was 0.32.
During the past 100 days, Prime Medicine Inc’s (PRME) raw stochastic average was set at 22.61%, which indicates a significant decrease from 99.10% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 89.49% in the past 14 days, which was higher than the 87.91% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.93, while its 200-day Moving Average is $5.87. Nevertheless, the first resistance level for the watch stands at $4.56 in the near term. At $4.75, the stock is likely to face the second major resistance level. The third major resistance level sits at $5.10. If the price goes on to break the first support level at $4.02, it is likely to go to the next support level at $3.67. The third support level lies at $3.48 if the price breaches the second support level.
Prime Medicine Inc (NASDAQ: PRME) Key Stats
The company with the Market Capitalisation of 525.73 million has total of 120,031K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -198,130 K annual income. Company’s last quarter sales were recorded 590 K and last quarter income was -45,760 K.
